As attention on the need for cheaper insulin intensifies, Mylan NV has secured a patent victory that positions it to launch a follow-on version of
Sanofi's Lantus (insulin glargine), which is pending at FDA. The US Patent and Trademark Office's Patent Trial and Appeal...






